(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2010 (24.06.2010)

PCT

(10) International Publication Number
WO 2010/070094 A1

(51) **International Patent Classification**:
C07K 16/22 (2006.01) ***A61P 21/00*** (2006.01)
A61K 39/395 (2006.01)

(21) **International Application Number**:
PCT/EP2009/067515

(22) **International Filing Date**:
18 December 2009 (18.12.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/138,980 19 December 2008 (19.12.2008) US

(71) **Applicant** *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **ASHMAN, Claire** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **BEATON, Andrew** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **ELLIS, Jonathan, Henry** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **HAN, Bajin** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **KIRBY, Ian** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **KULL, Frederick** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **LEWIS, Alan** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **LINDLEY, Kathryn, Mason** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **ORECCHIA, Martin, Anibal** [IT/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **SHEN, Ying** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **WILSON, Paul** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **XU, Tian Shun** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **ZHANG, Hong** [CN/US]; GlaxoSmithKline, 1250 S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426 (US).

(74) **Agent**: **BHOGAL, Jasber, Kaur**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/070094 A1

(54) **Title**: MYOSTATIN BINDING PROTEINS

(57) **Abstract**: Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. Furthermore, description of the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with any one or a combination of decreased muscle mass, muscle strength and muscle function.